Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model

Journal of Molecular Medicine

Volumn 79, Issue 10, 2001, Pages 587-593

  Wacheck, Volker ^a   Heere Ress, Elisabeth ^a   Halaschek Wiener, Julius ^a   Lucas, Trevor ^a   Meyer, Hildegard ^a   Eichler, Hans Georg ^a   Jansen, Burkhard ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antisense oligonucleotides; Apoptosis; Bcl 2; Chemoresistance; Gastric cancer

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CISPLATIN; OBLIMERSEN; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; MEASUREMENT; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SCID MOUSE; STOMACH CARCINOMA; TUMOR BIOPSY; TUMOR VOLUME; XENOTRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CISPLATIN; DNA, ANTISENSE; DOWN-REGULATION; FEMALE; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; SPECIFIC PATHOGEN-FREE ORGANISMS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034784534     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090100251     Document Type: Article

References (36)

1. Chemotherapy for gastric carcinoma: New and old options
2. Epidemiology of gastric cancer
3. 9th Seah Cheng Siang Memorial Lecture: Gastric cancer-where are we now?
4. The role of chemotherapy in the management of gastric cancer
5. Novel chemotherapeutic agents for gastrointestinal cancers
6. A phase II trial of low dose administration of 5-fluorouracil and cisplatin in patients with advanced and recurrent gastric cancer
7. Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma
8. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer
9. Apoptosis and chemotherapy resistance
10. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
11. Dysregulation of apoptosis in cancer
12. Involvement of the bcl-2 gene in human follicular lymphoma
13. BCL-2 family: Regulators of cell death
14. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
15. Immunohisto-chemical evaluation of bcl-2 protein expression in gastric adenocarcinomas
16. Prognostic value of bcl-2 expression in gastric cancer
17. Expression of Bcl-2 and Bax in human gastric cancer tissue
18. Bcl-2 expression as a prognostic factor of survival of gastric carcinoma
19. Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: Immunohistochemical and clinicopathological study
20. Predictive value of Bcl-2 and Bax protein expression for chemotherapeutic effect in gastric cancer. A pilot study
21. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
22. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
23. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
24. Chemosensitisation of malignant melanoma by BCL2 antisense therapy
25. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide
26. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin
27. Use of nude mouse xenografts as preclinical drug screens: In vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts
28. Bcl-2 antisense oligonucleotides (G3139) inhibit merkel cell carcinoma growth in SCID mice
29. Antisense therapy of hematologic malignancies
30. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice
31. Effect of preoperative 5-fluorouracil on apoptosis of advanced gastric cancer
32. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression
33. Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice
34. Mechanisms and therapeutic applications of immune stimulatory cpG DNA
35. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice
36. BCL-2 antisense oligodeoxynucleotide (ODN) (G3139) therapy exerts its anti-tumour action through a sequence-specific antisense effect, and not a cell-mediated immune response